Featured Research

from universities, journals, and other organizations

New Drug Combination May Prevent Dangerous Complication Of Bone Marrow Transplantation

Date:
December 12, 2002
Source:
Dana-Farber Cancer Institute
Summary:
A three-drug therapy, which includes a novel medication called sirolimus, reduces graft-versus-host disease (GVHD) in stem cell transplant patients more effectively and with less toxicity than traditional treatments, an ongoing clinical study by Dana-Farber Cancer Institute scientists suggests.

PHILADELPHIA -- A three-drug therapy, which includes a novel medication called sirolimus, reduces graft-versus-host disease (GVHD) in stem cell transplant patients more effectively and with less toxicity than traditional treatments, an ongoing clinical study by Dana-Farber Cancer Institute scientists suggests.

Related Articles


Interim results of the trial, which began two years ago, will be presented by researchers at the annual meeting of the American Society of Hematology in Philadelphia (Dec. 9, 4 p.m., Room 204).

The study seeks to produce better outcomes for patients receiving stem cell transplants for diseases such as leukemia and lymphoma. Such patients are at risk for GVHD, a condition in which transplanted immune cells mount an attack on patients' own tissue and organs. The drugs tacrolimus and methotrexate, though offering moderate control of GVHD, are associated with side effects such as kidney failure, high blood pressure, mouth sores, liver damage, and lowered white blood cell counts.

"These are very exciting early data," says the study's lead author, Joseph Antin, MD, of Dana-Farber. "We have been looking for ways of reducing transplant-related side effects for many years and these data tell us that we are on the right track. We are proceeding with further studies designed to eliminate methotrexate entirely while continuing to reduce toxicity and control GVHD."

Because sirolimus – a medication that interferes with the signaling mechanism in immune system cells – has been shown to work "synergistically" with tacrolimus, researchers theorized that low doses of the two drugs, in combination with methotrexate, might provide more effective control of GVHD with fewer side effects.

The 41-patient study is bearing out those hopes. Whereas 30 percent of unrelated donor transplant patients would normally be expected to develop severe GVHD, only 13 percent of the patients in the study have incurred that level of GVHD. The therapy produced no unusual side effects and patients' blood counts reached adequate levels.

Dana-Farber Cancer Institute (http://www.danafarber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.


Story Source:

The above story is based on materials provided by Dana-Farber Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Dana-Farber Cancer Institute. "New Drug Combination May Prevent Dangerous Complication Of Bone Marrow Transplantation." ScienceDaily. ScienceDaily, 12 December 2002. <www.sciencedaily.com/releases/2002/12/021212080856.htm>.
Dana-Farber Cancer Institute. (2002, December 12). New Drug Combination May Prevent Dangerous Complication Of Bone Marrow Transplantation. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2002/12/021212080856.htm
Dana-Farber Cancer Institute. "New Drug Combination May Prevent Dangerous Complication Of Bone Marrow Transplantation." ScienceDaily. www.sciencedaily.com/releases/2002/12/021212080856.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins